PRQR - ProQR gains on deal to divest eye disease therapies
2023-08-01 11:43:52 ET
More on ProQR
- ProQR: Too Many Failures For Its RNA Technology
- ProQR adds 75% as Cantor upgrades on expanded deal with Eli Lilly
- Eli Lilly sends ProQR 35% higher after expanding RNA editing deal
- AstraZeneca – LogicBio deal indicates more such takeovers are ahead – Cantor
- ProQR upgraded at Raymond James on RNA-editing platform
For further details see:
ProQR gains on deal to divest eye disease therapies